Navigation Links
Celator(R) Pharmaceuticals to Present at 2009 BIO International Convention
Date:5/13/2009

PRINCETON, N.J., May 13 /PRNewswire/ -- Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, is scheduled to present at the 2009 BIO International Convention in Atlanta. Mr. Jackson will provide a corporate overview and an update on the company's progress with two ongoing Phase 2 clinical trials of CPX-351 in newly diagnosed acute myeloid leukemia (AML) patients and first-relapse AML patients. The presentation will be held on Wednesday, May 20, 2009 at 3:40pm EDT in Room 311 of the Georgia World Congress Center.

About Celator Pharmaceuticals, Inc.

Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex(R), the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes: CPX-351 (a liposomal formulation of cytarabine:daunorubicin), currently in Phase 2 in patients with acute myeloid leukemia; CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in Phase 2 in patients with colorectal cancer; CPX-571 (a liposomal formulation of irinotecan:cisplatin), a preclinical stage compound; and multiple research programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov.


'/>"/>
SOURCE Celator Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research
2. Celator(R) Pharmaceuticals to Present at Future Leaders in the Biotech Industry Conference
3. Celator(R) Pharmaceuticals Enrolls First Patient in Its Phase 2 Study of CPX-351 in Acute Myeloid Leukemia in First Relapse
4. Celator(R) Pharmaceuticals To Present at Biotech Showcase 2009
5. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
6. Frederick R. Appelbaum, M.D. and Ross C. Donehower, M.D. Join Scientific Advisory Board of Celator(R) Pharmaceuticals
7. Arena Pharmaceuticals to Present at the 34th Annual Deutsche Bank Health Care Conference
8. Onyx Pharmaceuticals to Present at the Deutsche Bank 34th Annual Health Care Conference
9. Jiangbo Pharmaceuticals, Inc. to Present at CCG IRs China Rising Conference in New York
10. Vion Pharmaceuticals Reports 2009 First Quarter Results
11. Jiangbo Pharmaceuticals Announces New Ticker (JGBO) and CUSIP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... 2017 , ... “Beyond and Back”: a true-life testimony of tragedy and the ... author Bonetta Rose, a wife, mother and grandmother committed to sharing her many spiritual ... Bonetta Rose‘s new book presents actual events in the life of her family, which ...
(Date:3/23/2017)... ... March 23, 2017 , ... “A Respectful Response To ... Response To Atheist Manifesto” is the creation of published author Richard Hostetter, a ... sixty years. He holds graduate degrees from Kent State University and the University ...
(Date:3/22/2017)... ... March 23, 2017 , ... Death anxiety is unconscious and needs understanding and ... was inspired to write the book titled “ As Good as Goodbyes Get ” ... sense of what she was experiencing at the bedside of patients who were dying. ...
(Date:3/22/2017)... Jose, CA (PRWEB) , ... March 22, 2017 ... ... San Jose, Santa Cruz and Milpitas with a robust, ongoing community enrichment program, ... Housing (FSH), a nonprofit organization which has provided for the critical needs of ...
(Date:3/22/2017)... Ramon, CA (PRWEB) , ... March 22, 2017 ... ... tissue recovery agency for northern California and Nevada and LABS, Inc., announced the ... rapid turnaround (STAT) infectious disease screening and serology testing used to determine ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... 2017 Hologic, Inc. (Nasdaq: HOLX ... of Cynosure, Inc., a leader in medical aesthetics systems ... "We are pleased to complete our acquisition of ... Davin and the entire Cynosure team to achieve ... aesthetics market," said Steve MacMillan , Hologic,s Chairman, ...
(Date:3/22/2017)... 2017 FinancialBuzz.com News Commentary ... industry is strongly contributing to job creation. A recent ... reporting for the cannabis industry, projects that by 2020, ... quarter million jobs for American workers. The legal cannabis ... and is projected to grow at a compound annual ...
(Date:3/22/2017)... , March 22, 2017   Upsher-Smith Laboratories, Inc . ... USP, 25 mg, 50 mg and 75 mg, the generic ... USP. The clomipramine hydrochloride capsules market had ... ending December 2016, according to IMS Health. ... "Upsher-Smith has long been ...
Breaking Medicine Technology: